Granules India Q4 Consol Net Profit Rises 8.39% to Rs 129.65 Cr

Consolidated net profit of Granules India rose 8.39% to 129.65 crore rupees in the quarter ended March 2024 compared to 119.61 crore rupees during the same quarter ended March 2023. 

Key Takeaways from Granules India’s Performance: 

• Consolidated net profit rose 8.39% to 129.65 crore rupees.
• Sales declined 1.65% to 1,175.78 crore rupees.
• The board recommended a final dividend of Rs 1.50 per share.

However, revenue from operations declined 1.65% to 1,175.78 crore rupees in the fourth quarter ending March 2024 against 1,195.50 crore rupees during the previous quarter ended March 23.

For the full year, consolidated net profit plummeted 21.54% to 405.31 crore rupees in the year ended March 2024 against 516.60 crore rupees in the year ending March 2023. 

Further, sales declined 0.12% to 4,506.37 in the year ending March 2024 compared to 4,511.92 crore rupees during the previous year ended March 2023.

Granules India Announced that its Board of Directors of the company recommended a final dividend of Rs 1.50 per share, subject to shareholders' approval.

About Granules India Limited:

Granules India Limited, established in 1991 is a fast-growing Indian pharmaceutical company headquartered in Hyderabad. The company is among the few pharmaceutical companies in the world to be present in the manufacturing of the entire value chain from active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. The products of this pharmaceutical company are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK.

Read More About Granules India Limited Share Price Here!